UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 2, 2017

RESHAPE LIFESCIENCES INC.

(Exact name of registrant as specified in its charter)

(651) 634-3003

(Registrant’s telephone number, including area code)

Not applicable.

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Explanatory Note

On October 3, 2017, ReShape Lifesciences Inc. (formerly known as EnteroMedics Inc.), a Delaware corporation (the “Company”), filed a Current Report on Form 8-K (the “Original Report”) with the Securities and Exchange Commission to report that effective as of  October 2, 2017, the Company completed the acquisition of ReShape Medical, Inc., a Delaware corporation (“ReShape Medical”), through the merger of Nixon Subsidiary Inc., a Delaware corporation and wholly owned subsidiary of the Company, with and into ReShape Medical, and subsequent merger of ReShape Medical with and into Nixon Subsidiary Holdings LLC (now known as ReShape Medical LLC), a Delaware limited liability company and wholly owned subsidiary of the Company (the “Merger”).

This amendment to the Original Report is being filed to provide the financial statements and pro forma financial information required by Items 9.01(a) and 9.01(b), respectively, of Form 8-K.

Item 9.01              Financial Statements and Exhibits.

(a)   Financial Statements of Businesses Acquired.

The audited financial statements of ReShape Medical as of and for the years ended December 31, 2016 and December 31, 2015 and the unaudited interim financial statements of ReShape Medical as of and for the three and nine months ended September 30, 2017 are filed as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, and are incorporated by reference.

(b)  Pro Forma Financial Information.

The unaudited pro forma balance sheet as of September 30, 2017 and unaudited pro forma statements of income for the nine months ended September 30, 2017 and the year ended December 31, 2016 and the notes to such unaudited pro forma financial statements, all giving effect to the Merger, are filed as Exhibit 99.4 and incorporated by reference.

(c)  Shell Company Information.

Not applicable.

(d)  Exhibits.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 15, 2017

3

Exhibit 23.1

Consent of Independent Auditors

We consent to the incorporation by reference in the following Registration Statements:

(1)         Registration Statement (Form S-8 Nos. 333-211940, 333-196646, 333-184181, 333-176174, 333-171244, 333-159592, and 333-149662) of ReShape Lifesciences, Inc.,

(2)         Registration Statement (Form S-3 Nos. 333-216600, 333-205353, 333-195855, 333-183313, 333-171944, 333-171052, 333-166011, 333-161702, and 333-158516) of ReShape Lifesciences, Inc., and

(3)         Registration Statement (Form S-1 Nos. 333-215590, 333-171052, 333-143265, 333-170503, and 333-213704) of ReShape Lifesciences, Inc.;

of our report dated May 25, 2017, with respect to the December 31, 2016 financial statements of ReShape Medical, Inc., included in Amendment No. 1 to this Current Report on Form 8-K of ReShape Lifesciences, Inc.

Exhibit 23.2

CONSENT OF INDEPENDENT AUDITORS

We consent to the incorporation by reference in Registration Statements Nos. 333-211940, 333-196646, 333-184181, 333-176174, 333-171244, 333-159592, and 333-149662 on Form S-8, Registration Statement Nos. 333-216600, 333-205353, 333-195855, 333-183313, 333-171944, 333-171052, 333-166011, 333-161702, and 333-158516 on Form S-3, and Registration Statement Nos. 333-215590, 333-171052, 333-143265, 333-170503, and 333-213704 on Form S-1 of ReShape Lifesciences Inc. (the “Company”) of our report dated May 26, 2016, except for the restatement discussed in Note 1, for which the date is December 15, 2017, with respect to the balance sheet of ReShape Medical, Inc. as of December 31, 2015, and the related statements of operations, stockholders’ equity (deficit), and cash flows for the year then ended, which report appears in the Form 8-K/A of Reshape Lifesciences Inc. dated December 15, 2017.

Exhibit 99.1

Financial Statements with Report of Independent Auditors

As of December 31, 2016 and for the Year Then Ended

RESHAPE MEDICAL, INC.

YEAR ENDED DECEMBER 31, 2016

Table of Contents

Report of Independent Auditors

The Board of Directors

ReShape Medical, Inc.

We have audited the accompanying financial statements of ReShape Medical, Inc. which comprise the balance sheet as of December 31, 2016, and the related statements of operations and comprehensive loss, stockholders’ deficit and cash flows for the year then ended, and the related notes to the financial statements.

Management’s Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in conformity with U.S. generally accepted accounting principles; this includes the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

Auditor’s Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of ReShape Medical, Inc. at December 31, 2016, and the results of its

operations and its cash flows for the year then ended in conformity with U.S. generally accepted accounting principles.

The Company’s Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has recurring losses from operations and negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern.  Management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter.

RESHAPE MEDICAL, INC.

Balance Sheet

See accompanying notes to financial statements.

3

RESHAPE MEDICAL, INC.

Balance Sheet (continued)

See accompanying notes to financial statements.

4

RESHAPE MEDICAL, INC.

Statement of Operations and Comprehensive Loss

See accompanying notes to financial statements.

5

RESHAPE MEDICAL, INC.

Statement of Stockholders’ Deficit

For the Year Ended December 31, 2016

See accompanying notes to financial statements.

6

RESHAPE MEDICAL, INC.

Statement of Cash Flows

See accompanying notes to financial statements.

7

RESHAPE MEDICAL, INC.

Statement of Cash Flows (continued)

See accompanying notes to financial statements.

8

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

1.                                      Business and Significant Accounting Policies

Business

ReShape Medical, Inc. (the “Company”) was originally incorporated on August 22, 2005, under the name Abdominis, Inc., pursuant to the laws of the State of Delaware.  In January 2007, the Company changed its name from Abdominis, Inc. to ReShape Medical, Inc.  The Company has developed and currently markets and sells a U.S. Food and Drug Administration (FDA) approved unique non-surgical product for the treatment of obesity in the United States (U.S.).

Basis of Presentation. Management’s Plans and Liquidity

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position, results of operations and cash flows.

The Company has incurred operating losses and has experienced negative cash flows from operations since inception and has an accumulated deficit of $89,092,421 as of December 31, 2016. The Company used cash in its operations of $17,091,130 during the year ended December 31, 2016.  In August of 2015, the Company received U.S. FDA approval of its product and began selling in the U.S. in October 2015.  Successful development of the market for the Company’s products and its ability to grow sales is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s continued ability to raise capital and to generate cash from future revenue and operations adequate to support the Company’s cost structure.

As of December 31, 2016, the Company has cash and equivalents of $4,641,125. On January 31, 2017, the Company received proceeds of $11 million from the issuance of convertible debt to its Series D preferred stock investors. On February 1, 2017 the Company received net proceeds of $3.5 million from the completion of an amendment to its current debt agreement with its bank.  The Company performed an analysis and concluded substantial doubt exists with respect to the Company being able to continue as a going concern through one year from the date of issuance of the financial statements for the year ended December 31, 2016. In order to meet its operating cash flow requirements, management’s plans include raising capital through the issuance of equity and debt instruments.  While the Company’s management believes that it will continue to be successful in obtaining the necessary financing to fund its operations, there are no assurances that such additional funding will be achieved on acceptable terms, or at all. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, result of operations, and future prospects,

9

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

1.                                      Business and Significant Accounting Policies (continued)

Basis of Presentation. Management’s Plans and Liquidity (continued)

including its ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing estimates and assumptions that are used in the preparation of these financial statements.  Management must apply significant judgment in this process.  In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends.  The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. The most significant estimates in the accompanying financial statements relate to the valuation of the Company’s common stock, warrants, other equity awards, provision for product warranty, and obsolete and slow-moving inventory. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements under different assumptions or conditions.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less, when acquired, to be cash equivalents. Substantially all of the Company’s cash and cash equivalents are maintained at one financial institution domiciled in the United States. Amounts on deposit with this financial institution may, from time to time, exceed the federally-insured limit, as well as coverage provided by the Securities Investment Protection Corporation.  As of December 31, 2016 all of the Company’s cash and cash equivalents are held in readily available checking and money market accounts.

Short-term Investments

Short-term investments are comprised of commercial paper and corporate obligations with original maturity dates greater than ninety days and less than one year. The Company classifies its short-term investments as

10

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

1.                                      Business and Significant Accounting Policies (continued)

Short-term Investments (continued)

available for sale securities with net unrealized gains or losses recorded as a component of stockholders’ deficit. Realized gains and losses are included as other income (expense) in the statement of operations and comprehensive loss. The cost basis for realized gains and losses on available-for-sale securities is determined on a specific identification basis. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date. The Company periodically reviews its investments for other than temporary declines in fair value below the cost basis and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. As of December 31, 2016 there were no short-term investments held by the Company.

Accounts Receivable

Trade accounts receivable are stated at the amount the Company expects to collect. The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. Management considers the following factors when determining the collectability of specific customer accounts: customer credit worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. Based on management’s assessment, the Company provides for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. The Company recorded a valuation allowance of $38,355 as of December 31, 2016.

Inventories

Inventories are valued at the lower of cost, determined on a first-in, first-out (“FIFO”) basis, or market. Management evaluates inventory for excess quantities and obsolescence and records an allowance to reduce the carrying value of inventory as determined necessary.

Property and Equipment

Property and equipment are recorded at cost.  The Company provides for depreciation over estimated useful lives of two to three years, or the life of the related lease for leasehold improvements, if shorter, using the straight-line method.  Repairs and

11

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

1.                                      Business and Significant Accounting Policies (continued)

maintenance expenditures that do not significantly add value to property and equipment, or prolong its life, are charged to operations as incurred.  Gains and losses on dispositions of property and equipment are included in the operating results of the related period.

Impairment of Long-lived assets

The Company will record impairment losses on long-lived assets used in operations when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets.  An impairment analysis is subjective and assumptions regarding future growth rates and operating expense levels can have a significant impact on the expected future cash flows and impairment analysis.  In December 2016, the Company recognized an impairment of $208,383 for leasehold improvements due to its plan to move to a new facility.  The amount is included in impairment charges and lease termination cost in the statement of operations and comprehensive loss.

While the Company’s current and historical operating losses and cash flows are indicators of impairment, the Company believes that future cash flows from operating activities and financing activities will exceed the carrying value of its long-lived assets and accordingly, exclusive of the above, the Company has not recognized any other impairment losses through December 31, 2016.

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, short-term investments and accounts receivable. The Company maintains balances that at times may exceed amounts that are federally-insured or insured by the Securities Investor Protection Corporation. Management mitigates such potential risks by maintaining the Company’s cash and short-term investment balances with entities that management believes possess high-credit quality and does not anticipate any losses with regards to these amounts.

The Company believes the concentration of credit risk in its accounts receivable is mitigated by its credit evaluation process, relatively short collection terms and the level of credit worthiness of its customers.

12

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

1.                                      Business and Significant Accounting Policies (continued)

Fair Value Measurements

The Company measures fair value based on a three-level hierarchy of inputs, of which the first two are considered observable and the last unobservable.  Unobservable inputs reflect the Company’s own assumptions about current market conditions. The three-level hierarchy of inputs is as follows:

·                  Level 1 — Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities.

·                  Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

·                  Level 3 - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

The fair value of the Company’s financial assets and liabilities measured on a recurring basis is as follows:

The fair value of the Company’s cash equivalents were determined using Level 1 inputs.  Unadjusted quoted prices for these securities are regularly provided to the Company by independent pricing services.

The fair value of the Company’s Series C Preferred Stock warrants were determined by the use of the Black-Scholes option-pricing model under the following assumptions:

13

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

1.                                      Business and Significant Accounting Policies (continued)

Fair Value Measurements (continued)

Given the absence of a public trading market, the Company determined the fair value of the Series C Preferred Stock through the use of objective and subjective factors.  These factors included, but were not limited to (i) valuations performed by unrelated third-party specialists which included fair value estimates about the Company’s securities and (ii) the prices for Series C Preferred Stock sold in the Company’s preferred stock purchase agreements.

Stock warrants

The Company has issued freestanding warrants to purchase shares of its convertible preferred stock which are accounted for as a liability due to the nature of the underlying redemption provisions of the preferred stock into which the warrants are exercisable. The warrants are recorded on the Company’s balance sheet at their fair value as determined on the date of issuance and are revalued at each subsequent balance sheet date, with fair value changes recognized as other income or expense in the accompanying statement of operations and comprehensive loss. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrants, the completion of a deemed liquidation event, the conversion of convertible preferred stock into common stock, or until the holders of the convertible preferred stock can no longer trigger a deemed liquidation event. Pursuant to the terms of these warrants, upon the conversion of the class of preferred stock underlying the warrant, the warrants automatically become exercisable for shares of the Company’s common stock based upon the conversion ratio of the underlying class of preferred stock. The consummation of an initial public offering will result in the conversion of all classes of the Company’s preferred stock into common stock. Upon such conversion of the underlying classes of preferred stock, the warrants will be classified as a component of equity and will no longer be subject to re-measurement. The Company estimates the fair value of the liability using option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, including assumptions for expected volatility, expected life, yield, and risk-free interest rate.

14

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

1.                                      Business and Significant Accounting Policies (continued)

Stock warrants (continued)

A summary of preferred stock warrant activity for the year ended December 31, 2016 is as follows:

There were no transfers between levels within the fair value hierarchy during the periods presented.

Revenue Recognition

Revenue is recognized when persuasive evidence of the arrangement exists, delivery and performance has occurred, the price is fixed and determinable and collectability is probable. Generally, these criteria are met at the time products are shipped. Provisions for discounts are recorded and are classified as reductions to revenues.

Shipping and Handling

The Company records amounts invoiced to its customers for outbound freight and shipping as revenue and the related expense as cost of goods sold.

Warranty Accrual

The Company’s products are covered by a one year warranty policy against defective products at the time of shipment. In the event that a product is defective, the Company may replace the product or refund the purchase price or a portion thereof. The Company estimates future warranty costs by analyzing the timing, cost and amount of returned

15

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

1.                                      Business and Significant Accounting Policies (continued)

product and by considering future expectations. Assumptions and historical warranty experience are evaluated periodically to determine the continued appropriateness of such assumptions. The Company recorded a reserve for warranty claims in the amount of approximately $171,000 as of December 31, 2016, which is included within accrued and other liabilities on the accompanying balance sheet.

Foreign Currency

The Company maintains a foreign bank account for purposes of collecting trade receivables from foreign customers. Foreign bank balances are translated at the rates of exchange at  the balance sheet date. Gains and losses resulting from foreign currency transactions are recorded within other income in the accompanying statement of operations and comprehensive loss.

Patent-related Expenditures

Expenditures related to patent research and applications, which are primarily comprised of legal fees, are expensed as incurred.

Research and Development

Research and development costs are expensed when incurred.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Accordingly, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse. Current income taxes are based on the year’s taxable income for federal and state income tax reporting purposes. The likelihood of realizing the tax benefits related to a potential deferred tax benefit is evaluated, and a valuation allowance is recognized to reduce that deferred tax asset if it is more likely than not that all or some portion of the deferred tax asset will not be realized.

The Company’s net deferred tax assets at December 31, 2016 and consist principally of net operating losses and the Company provided a 100% valuation allowance for the tax effect of these net operating losses. No benefit for income taxes has been provided in the accompanying statements of operations and comprehensive loss since all deferred tax assets have been fully reserved. The Company provided the valuation allowance since management could not determine that it was “more likely than not” that the benefits of the deferred tax assets would be realized.

16

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

1.                                      Business and Significant Accounting Policies (continued)

The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions.  The preparation of these state tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company.

Uncertain Tax Positions

GAAP prescribes a comprehensive model for how a company should recognize, measure, present, and disclose in its financial statements uncertain tax positions that it has taken or expects to take on a tax return. A favorable tax position may be included in the calculation of tax liabilities and expenses if a company concludes that it is more likely than not that its adopted tax position will prevail if challenged by tax authorities. Where applicable, associated interest and penalties are also recorded. The Company did not recognize any adjustments regarding its tax accounting treatments for the year ended December 31, 2016. The Company is subject to continuous examination of its income tax returns by the U.S. Internal Revenue Service and other tax authorities since inception.

Stock-based Compensation

The Company accounts for stock options granted to employees, directors and consultants using a fair value method, which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options. The Company’s employee share-based awards result in a cost that is measured at fair value on the awards’ grant date, using a Black-Scholes option-pricing model, based on the estimated number of awards that are expected to vest. Stock-based compensation is recognized on a straight-line basis over the award vesting period.

Transactions with non-employees in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date on which it is probable that performance will occur.

The Black-Scholes option-pricing model requires assumptions, such as the value of the Company’s common stock, the risk-free interest rate, dividend yield, expected term and expected volatility. Further, the forfeiture rate also affects the amount of aggregate compensation. The following assumptions are subjective and generally require significant management judgment:

17

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

1.                                      Business and Significant Accounting Policies (continued)

Stock-based Compensation (continued)

Common stock value — the fair value of the shares of common stock underlying stock options is determined by the Company’s Board of Directors (the “Board”) for the stock option plan. Since there is no public market for the common stock, the Board determines the common stock fair value at the time of each option grant by considering a number of objective and subjective factors. These include the valuation of several public peer group companies within the medical device industry that focus on technological advances and development that the Board believes is comparable to the Company’s operations. Factors such as operating and financial performance, the lack of liquidity of the common stock and trends in the broader economy and medical device industry also have an impact on the determination of the fair value of the common stock. In addition, the Company regularly engages a third party valuation specialist to assist with estimates related to the valuation of the common stock.

Expected volatility — Since the Company does not have sufficient stock price history to estimate the expected volatility of its shares, the expected volatility is calculated based on the average volatility for a public company peer group in the industry in which the Company does business.

Dividend yield of zero — The Company has not paid, and does not intend to pay, dividends.

Risk-free interest rates — The Company applies the risk-free interest rate based on the U.S. Treasury yield for the expected term of the option.

Expected term — For employees, the Company calculated the expected term using the “simplified method”, which represents the average of the contractual term of the option and the vesting period for its employee stock options.  For non-employees, the Company estimated the expected term as the contractual term of the award.

Forfeiture rate — estimated at the time of the grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Comprehensive Income (Loss)

Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events from non-owner sources. The components of comprehensive income (loss), including net loss, are reported in the financial statements in the period in which they are recognized. Net loss and other comprehensive loss shall be reported, net of their related tax effect to arrive at comprehensive loss. The Company did not have any  unrealized income or losses on short-term investments to recognize for the year ended December 31, 2016.

18

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

1.                                      Business and Significant Accounting Policies (continued)

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) ASU 2014-09 regarding ASC Topic 606, Revenue from Contracts with Customers. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance becomes effective for the Company beginning fiscal year 2019 with early adoption permitted as of January 1, 2017.  Management is currently evaluating the accounting, transition and disclosure requirements of the standard to determine the financial statement impact of adoption.

In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern. The standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued and provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. Certain disclosures are required if conditions given rise to substantial doubt about an entity’s ability to continue as a going concern. ASU 2014-15 was adopted by the Company effective December 31, 2016 and these financial statements disclose management’s conclusion with respect to substantial uncertainty about the Company’s ability to continue as a going concern for twelve months from the date these financial statements are issued.

In July 2015, FASB issued ASU 2015-11, Inventory regarding ASC Topic 330, Simplifying the Measurement of Inventory. Topic 330 currently requires an entity to measure inventory at the lower of cost or market, where market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. This ASU limits the scope to inventory that is measured using first-in, first-out (FIFO) or average cost and requires inventory be measured at the lower of cost or net realizable value. The new standard is effective for fiscal years beginning after December 15, 2016 and interim periods within fiscal years beginning after December 15, 2017. Management is currently evaluating the accounting, transition and disclosure requirements of the standard to determine the financial statement impact of adoption.

19

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

1.                                      Business and Significant Accounting Policies (continued)

Recent Accounting Pronouncements (continued)

In February 2016, the FASB issued ASU 2016-02, Leases, which requires lessees to recognize “right of use” assets and liabilities for all leases with terms of more than 12 months. The ASU requires additional quantitative and qualitative financial statement note disclosures about the leases, significant judgments made in accounting for those leases and amounts recognized in the financial statements about those leases. The guidance will be effective for the Company in 2020 with early adoption permitted. Management is evaluating the impact that adopting this guidance will have on the financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718).  The new standard requires income tax effects of stock compensation awards to be recognized in the income statement when the awards vest or are settled.  The new standard also allows the Company to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur.  The new standard is effective for annual periods beginning after December 15, 2017, and early adoption is permitted. The Company is currently evaluating the impact of ASU 2016-09 on its financial statements. Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

2.                                      Inventories

Inventories, net consisted of the following at December 31:

3.                                      Property and Equipment

Property and equipment, net consisted of the following at December 31:

20

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

Depreciation and amortization expense for the year ended December 31, 2016 was $243,292.

4.                                      Notes Payable and Warrants Issued to Bank

February 2013 Debt Financing

In February 2013, the Company signed a loan and security agreement with a bank.  In connection with the agreement, the Company issued warrants to purchase 243,902 shares (the “Initial Shares”) of the Company’s Series C Preferred Stock at a purchase price of $0.82 per share.  The fair value of the Initial Shares was determined by using the Black-Scholes option-pricing model, with the following assumptions: (i) no expected dividends; (ii) a risk-free interest rate of 1.38%; (iii) expected volatility of 53.0%; and (iv) an expected life of the warrants of seven years.  The fair value of the Initial Shares was capitalized as loan issue costs of $107,986 and is amortized to interest expense over the term of the loan on a straight-line method. The issued warrants expire on February 12, 2020, subject to automatic exercise upon expiration. At December 31, 2016 there were 243,902 warrants fully-vested and outstanding, recorded as a liability with a fair value of $96,311.

In addition to the Initial Shares granted to the bank, on March 27, 2014, the Company issued to the bank warrants to purchase an additional 121,951 shares (the “Tranche B Shares”) of the Company’s Series C Preferred Stock at a purchase price of $0.82 per share. The fair value of the Tranche B Shares was determined by using the Black-Scholes option-pricing model, with the following assumptions: (i) no expected dividends; (ii) a risk-free interest rate of 1.38%; (iii) expected volatility of 55.0%; and (iv) an expected life of the warrants of 7.0 years.  The fair value of the Tranche B Shares was recorded as a debt discount of $65,347 and is amortized to interest expense over the term of the loan using the straight-line method. The issued warrants expire on February 12, 2020, subject to automatic exercise upon expiration. At December 31, 2016 there were 121,951 warrants fully-vested and outstanding, recorded as a liability with a fair value of $53,991.

21

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

4.                                      Notes Payable and Warrants Issued to Bank (continued)

March 2015 Debt Financing

In March 2015, the Company signed a loan and security agreement (“Loan Agreement”) with two co-lenders. Under the terms of the Loan Agreement, the Company borrowed $7,000,000 on March 31, 2015.   Under the terms of the Loan Agreement, the Company shall make monthly payments of interest only commencing on the funding date and continuing up to the amortization date, which was November 1, 2016. Beginning on the amortization date, the Company shall make equal monthly payments of principal plus interest over a period of thirty months. The principal amount outstanding shall accrue interest at a floating per annum rate equal to the greater of 8.15% or the sum of the three month LIBOR rate plus 7.89% (8.56% at December 31, 2016). All unpaid principal and accrued interest is due and payable by April 1, 2019.

In addition to the above principal and interest payments, a final payment equal to 5.25% percent of the initial principal balance is due upon termination of the loan (“Final Payment”). The Final Payment is $367,500 and was accrued at the commencement of the Loan Agreement with an offsetting accrual to unamortized debt discount.  The Final Payment is being amortized to interest expense, on straight-line basis, over the term of the Loan Agreement.  During 2016, $91,875 was amortized and included in interest expense in the statement of operations and comprehensive loss. At December 31, 2016, the Final Payment, net of unamortized debt discount of $206,723, is $160,777 and is recorded and included in Notes Payable. The loan is collateralized by certain assets of the Company.

In connection with the above Loan Agreement, the Company issued warrants to purchase 426,830 shares of the Company’s Series C Preferred Stock at a purchase price of $0.82 per share.  The fair value of the warrants was determined by using the Black-Scholes option-pricing model, with the following assumptions: (i) no expected dividends; (ii) a risk-free interest rate of 1.94%; (iii) expected volatility of 52.5%; and (iv) an expected life of the warrants of ten years.  The fair value of the warrants was recorded as loan issue costs of $257,200 and is amortized to interest expense over the term of the loan using the straight-line method. The issued warrants expire on March 31, 2025, subject to automatic exercise upon expiration if they meet certain contingencies. At December 31, 2016, there were 426,830 warrants fully-vested and outstanding, recorded as a liability with a fair value of $249,183.

The aggregate annual maturities of the note payable are as follows:

22

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

5.                                      Convertible Promissory Notes and Warrants

Convertible Promissory Notes and Warrants Issued in 2014 and 2015

In June 2014, the Company entered into a Note and Warrant Purchase Agreement (the “Purchase Agreement”) whereby convertible promissory notes (the “Notes” or “Note”) and warrants to purchase Series C preferred stock (the “Warrants”) were issued to certain stockholders in exchange for cash (“Initial Closing”).  The Notes issued in the Initial Closing have an aggregate principal amount of $4,000,000. In December 2014, the Purchase Agreement was amended whereby additional Notes in the aggregate principal amount of $1,250,000 and Warrants were issued to certain stockholders in exchange for cash (“Second Closing”). In January 2015, the Purchase Agreement was amended whereby additional Notes in the aggregate principal amount of $1,500,000 and Warrants were issued to certain stockholders in exchange for cash (“Third Closing”). In March 2015, the Purchase Agreement was amended whereby additional Notes in the aggregate principal amount of $2,000,000 and Warrants were issued to certain stockholders in exchange for cash (“Fourth Closing”).

The Notes accrued interest at a rate of 8% per annum on the outstanding principal balance.  In August 2015, the Company entered into a stock purchase agreement whereby an aggregate amount of 8,309,122 shares of Series D Convertible Preferred Stock were issued in exchange for conversion of the Indebtedness to the Note holders totaling $9,341,945.

In connection with the Notes issued under the Purchase Agreement (as amended), the Company issued Warrants to the Note holders to purchase 1,219,510, 381,093, 457,314 and 609,754 shares of the Company’s Series C Preferred Stock on the First, Second, Third and Fourth Closings, respectively. The Warrants have an exercise price of $0.82 per share. The Warrants were fully exercisable on the date of issuance and expire ten years from the issuance date.

23

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

The fair value of the Warrants as of the issuance date was $768,497, $240,153, $274,693 and $366,258 for the Warrants issued on the First, Second, Third and Fourth Closings, respectively. The fair value was determined using the Black-Scholes option-pricing model with the following assumptions:

The fair value of the Warrants is presented as a debt discount on the Notes and amortized to interest expense over the term of the related Notes using the effective interest method and as a liability on the accompanying balance sheet, which is revalued at each reporting period until the warrants are exercised or expire.  As of December 31, 2016, the warrants are recorded as a liability with a fair value of $1,516,787.

6.                                      Stockholders’ Equity

Preferred Stock

The Company has authorized 71,152,828 shares of Preferred Stock with a par value of $0.0001.  The Preferred Stock is divided into series.  The first series consists of 500,000 authorized shares and is designated Series S Convertible Preferred Stock. The second series consists of 4,687,500 authorized shares and is designated Series A Convertible Preferred Stock. The third series consists of 6,250,000 authorized shares and is designated Series B Convertible Preferred Stock. The fourth series consists of 25,916,528 authorized shares and is designated Series C Convertible Preferred Stock. The fifth series consists of 33,798,800 authorized shares and is designated Series D Convertible Preferred Stock.

Series D Convertible Preferred Stock

In August 2015, the Company entered into a stock purchase agreement whereby an aggregate amount of 25,489,678 shares of Series D Convertible Preferred Stock were issued in exchange for $28,658,047 in cash (gross).  Additionally, 8,309,122 shares of Series D Convertible Preferred Stock were issued in August 2015 in exchange for conversion of Indebtedness to stockholders totaling $9,341,945 (Note 5).

24

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

6.                                      Stockholders’ Equity (continued)

Series D Convertible Preferred Stock (continued)

The Series D Convertible Preferred Stock contains a liquidation preference described below.  Shares of Series D Convertible Preferred Stock are convertible at the holder’s option into shares of common stock, initially on a share-for-share basis using a conversion rate of $1.12 per share.  The conversion ratio may be adjusted upon certain events and for certain dilutive issuances, splits and combinations.  Conversion is automatic in the event of a public offering of the Company’s common stock meeting certain specified criteria or upon the election of 67% of the holders of the Series D Preferred Stock, Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock and Series S Preferred Stock, voting together as a single class.

Dividends, if declared or upon the liquidation or winding up of the Company, are non-cumulative and are payable at the rate of 8% of the Series D Preferred Stock’s original issue price per annum on each share.  No dividends have been declared through December 31, 2016.  Each share of Series D Preferred Stock has voting rights equal to the number of shares of common stock into which it is then convertible. Shares of the Series D Preferred Stock are not redeemable.

In the event that the Company has an unrestricted cash position of less than $5,000,000 or the Board of Directors determines the Company must raise additional equity capital, other than an initial public offering, then each Investor holding shares of Series D Preferred Stock shall have the right to purchase a pro rata share of additional Series D Preferred Stock at the purchase price of $1.1243 per share (as adjusted for any stock dividends, contributions, splits, recapitalizations and the like with respect to such shares).  The amount of capital to be raised under these circumstances shall be the greater of $15,000,000 in net cash proceeds or an amount determined by the Board of Directors.

Series C Convertible Preferred Stock

In October 2012, the Company entered into a stock purchase agreement whereby an aggregate amount of 9,859,756 shares of Series C Convertible Preferred Stock were issued in two closings (October 2012 and December 2012) in exchange for $8,085,001 in cash.  Additionally, 3,747,141 shares of Series C Convertible Preferred Stock were issued in October 2012 in exchange for conversion of indebtedness to stockholders totaling $3,072,656. As a result of the indebtedness’ beneficial conversion feature, the Company recognized additional interest expense of $341,406 in 2012 and issued 416,349 shares of Series C Preferred Stock. Related issuance costs aggregated $91,422.

25

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

6.                                      Stockholders’ Equity (continued)

In March 2013, the Company completed the final closing of the Series C Preferred Stock purchase agreement whereby an aggregate amount of 8,432,928 shares of Series C Convertible Preferred Stock was issued in exchange for $6,915,001 in cash. Related issuance costs aggregated $17,842.

The Series C Convertible Preferred Stock contains a liquidation preference described below.  Shares of Series C Convertible Preferred Stock are convertible at the holder’s option into shares of common stock, initially on a share-for-share basis using a conversion rate of $0.82 per share.  The conversion ratio may be adjusted upon certain events and for certain dilutive issuances, splits and combinations.  Conversion is automatic in the event of a public offering of the Company’s common stock meeting certain specified criteria or upon the election of 67% of the holders of the Series D Preferred Stock, Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock and Series S Preferred Stock, voting together as a single class.

Dividends, if declared or upon the liquidation or winding up of the Company, are non-cumulative and are payable at the rate of 8% of the Series C Preferred Stock’s original issue price per annum on each share.  No dividends have been declared through December 31, 2016.  Each share of Series C Preferred Stock has voting rights equal to the number of shares of common stock into which it is then convertible. Shares of the Series C Preferred Stock are not redeemable.

Series B Convertible Preferred Stock

In October 2008, the Company entered into a stock purchase agreement whereby an aggregate amount of 6,250,000 shares of Series B Convertible Preferred Stock were issued in exchange for $20,000,000 in cash.  Related issuance costs aggregated $120,767.

The Series B Convertible Preferred Stock contains a liquidation preference described below.  Shares of Series B Convertible Preferred Stock are convertible at the holder’s option into shares of common stock on a share-for-share basis using a conversion rate of $1.59 per share.  The conversion ratio may be adjusted upon certain events and for certain dilutive issuances, splits and combinations.  Conversion is automatic in the event of a public offering of the Company’s common stock meeting certain specified criteria or upon the election of 67% of the holders of the Series D Preferred Stock, Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock and Series S Preferred Stock, voting together as a single class.

26

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

6.                                      Stockholders’ Equity (continued)

Dividends, if declared or upon the liquidation or winding up of the Company, are non-cumulative and are payable at the rate of 8% of the Series B Preferred Stock’s original issue price per annum on each share.  No dividends have been declared through December 31, 2016.  Each share of Series B Preferred Stock has voting rights equal to the number of shares of common stock into which it is then convertible. Shares of the Series B Preferred Stock are not redeemable.

Series A Convertible Preferred Stock

In May 2006, the Company entered into a stock purchase agreement whereby an aggregate amount of 2,812,500 shares of Series A Convertible Preferred Stock were issued in exchange for $4,500,000 in cash.  Related issuance costs aggregated $73,932.

In August 2007, the Company entered into a stock purchase agreement whereby an aggregate amount of 1,875,000 shares of Series A Convertible Preferred Stock were issued in exchange for $3,000,000 in cash.  Related issuance costs aggregated $22,408.

The Series A Convertible Preferred Stock contains a liquidation preference described below.  Shares of Series A Convertible Preferred Stock are convertible at the holder’s option into shares of common stock on a share-for-share basis using a conversion rate of $1.12 per share.  The conversion ratio may be adjusted upon certain events and for certain dilutive issuances, splits and combinations.  Conversion is automatic in the event of a public offering of the Company’s common stock meeting certain specified criteria or upon the election of 67% of the holders of the Series D Preferred Stock, Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock and Series S Preferred Stock, voting together as a single class.

Dividends, if declared or upon the liquidation or winding up of the Company, are non-cumulative and are payable at the rate of 8% of the Series A Preferred Stock’s original issue price per annum on each share.  No dividends have been declared through December 31, 2016.  Each share of Series A Preferred Stock has voting rights equal to the number of shares of common stock into which it is then convertible. Shares of the Series A Preferred Stock are not redeemable.

Series S Convertible Preferred Stock

In September 2005, the Company entered into a stock purchase agreement whereby an aggregate amount of 500,000 shares of Series S Preferred Stock were issued in exchange for $500,000 in cash.  Related issuance costs aggregated $39,998.

27

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

6.                                      Stockholders’ Equity (continued)

The Series S Convertible Preferred Stock contains a liquidation preference described below.  Shares of Series S Convertible Preferred Stock are convertible at the holder’s option into shares of common stock on a share-for-share basis using a conversion rate of $0.84 per share.  The conversion ratio may be adjusted upon certain events and for certain dilutive issuances, splits and combinations.  Conversion is automatic in the event of a public offering of the Company’s common stock meeting certain specified criteria or upon the election of 67% of the holders of the Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock and Series S Preferred Stock, voting together as a single class.

Dividends, if declared or upon the liquidation or winding up of the Company, are non-cumulative and are payable at the rate of 8% of the Series S Preferred Stock’s original issue price per annum on each share.  No dividends have been declared through December 31, 2016.  Each share of Series S Preferred Stock has voting rights equal to the number of shares of common stock into which it is then convertible. Shares of the Series S Preferred Stock are not redeemable.

Liquidation Preferences

Upon liquidation, dissolution or winding up of the Company, the holders of Series D Preferred Stock, on a pro rata basis, are entitled to receive, prior and in preference to any distribution from the assets of the Company to the holders of all other series of Preferred Stock and the holders of common stock, an amount per share equal to the original issue price of the Series D Preferred Stock, plus all declared but unpaid dividends.

After payment of the above amounts, the holders of the Series S Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock, on a pro rata basis, are entitled to receive, prior and in preference to any distribution from the assets of the Company to the holders of common stock, an amount per share equal to the original issue price of the Series S Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock, plus all declared but unpaid dividends.

After payment of the above amounts, the remaining assets of the Company available for distribution to the stockholders shall be distributed to the holders of the common stock.

28

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

6.                                      Stockholders’ Equity (continued)

Common Stock

The Company has authorized 105,000,000 shares of common stock with a par value of $0.0001.

In August 2005, the Company issued 1,625,000 shares of its common stock to founders in exchange for cash totaling $1,625.

In 2008, the Company issued 375,000 shares of the Company’s common stock to consultants, subject to the terms of the 2005 Stock Incentive Plan and Restricted Stock Award Agreements as consideration for services provided. The aggregate value of the shares at issuance was as follows:

The Company has a right of first refusal to purchase all or any shares offered for sale at the price specified in the offer. The rights provided the Company shall terminate upon the consummation of a public offering or immediately prior to the consummation of a change in control whereupon the shares will be exchanged for shares of a successor corporation, which corporation is publicly held.

In 2008, the Company issued 400,000 shares of the Company’s common stock to a key employee, subject to the terms of the 2005 Stock Incentive Plan and a Restricted Stock Purchase Agreement in exchange for cash of $100,000.  The restricted stock is subject to a right of first refusal as defined in the Restricted Stock Purchase Agreement.

During the year ended December 31, 2016, 113,624 shares of common stock were issued in exchange for cash of $24,469 upon the exercise of options.

Warrants

In November 2011, the Company issued warrants to an outside consultant to purchase 26,533 shares of the Company’s common stock at a per share price of $0.44 in exchange for services.  The warrants expire on November 22, 2021 and as of December 31, 2016 all the warrants are fully-vested and outstanding.

In August 2013, the Company issued warrants to an outside consultant to purchase 36,836 shares of the Company’s common stock at a per share price of $0.18 in exchange for services.  The warrants expire on August 22, 2023 and as of December 31, 2016 all the warrants are fully-vested and outstanding.

29

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

Common shares reserved for future issuance consisted of the following at December 31, 2016:

7.                                      Stock Options

The Company adopted the 2015 Stock Incentive Plan (the “2015 Plan”) on October 26, 2015, which provides for the issuance of shares of the Company’s common stock to employees, directors and consultants.  The exercise price of options granted under the 2015 Plan is established by the Company’s Board of Directors and no option shall have a term in excess of ten years from the option grant date.  Options vest in various installments as outlined in the related stock option agreements, or as determined by the Company’s Board of Directors. The 2015 Plan supersedes the previous 2005 Stock Incentive Plan (the “2005 Plan”) under which options were issued through October 25, 2015.  Shares of common stock authorized for issuance under the 2015 Plan, include any shares outstanding on October 25, 2015 under the 2005 Plan, that are subsequently cancelled or expired under their normal terms.

As of December 31, 2016, the Company has reserved up to 21,805,357 shares of its common stock, consisting of 8,293,315 shares related to outstanding options granted under the 2005 Plan and 13,512,042 shares authorized, as described above, under the 2015 Plan

30

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

7.                                      Stock Options (continued)

to provide for the issuance of shares of the Company’s common stock to employees, directors and consultants under its stock option plan.

In 2016 the Company granted 9,214,009 of options to its employees.  During the year ended December 31, 2016 the Company recorded stock-based employee compensation expense of $293,766. Stock-based employee compensation expense was determined using the fair value of stock options as of the grant date.

In 2016 the Company granted 1,517,657 of options to non-employees in exchange for services. During the year ended December 31, 2016 the Company recorded stock-based compensation expense to non-employees of $79,298 in connection with non-employee options earned.

The fair value of each option grant was estimated using the Black-Scholes option pricing model with the following assumptions:

The weighted average grant date fair value of all stock options granted during the year ended December 31, 2016 is $0.17.

Stock Option Activity

A summary of stock option activity in 2016 is as follows:

The intrinsic value of options exercised during 2016 was $14,163.

31

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

7.                                      Stock Options (continued)

The following table summarizes information concerning outstanding, vested, expected to vest and exercisable stock options at December 31, 2016:

As of December 31, 2016 total compensation cost related to nonvested options not yet recognized is $1,380,384, and the weighted average period over which this amount is expected to be recognized is 3.5 years.

8.                                      Commitments and Contingencies

Operating Leases

In December 2016, the Company approved a plan for the early termination and exit of the operating lease for its existing headquarter office location in San Clemente, California.  As part of the plan to exit the lease, the Company recognized a charge in the amount of $674,025 related to the impairment of leasehold improvements, certain remaining minimum lease payments and lease termination expenses.  The amount is shown as impairment charge and lease termination charges in the statement of operations and comprehensive loss.

In January 2017, the Company entered into an operating lease for a facility to serve as its new headquarter office in a separate location of San Clemente, California. The lease commences on April 1, 2017 and expires on June 30, 2022.

In January 2017, the Company extended an operating lease for its manufacturing facility. The extension was to a prior lease on the same property dated October 12, 2015. The January 2017 lease amendment extended the terms of the lease through October 31, 2019.

32

RESHAPE MEDICAL, INC.

Notes to the financial statements (continued)

8.                                      Commitments and Contingencies (continued)

Operating Leases (continued)

Future minimum lease payments required under these leases are as follows for the years ending December 31:

Rent expense for the years ended December 31, 2016 was $605,693.

Litigation

On April 20, 2017, a company filed a Complaint in Federal Court in the District of Delaware accusing ReShape Medical, Inc. of trade secret misappropriation under the California Uniform Trade Secrets Act (CA. Civ. Code §3426 et seq.) and/or Delaware law (Code Ann. Title 6 §2001 et seq); and infringement of U.S. Patent Nos. 9,445,930 and 9,456,915.  Management of the Company intends to vigorously defend against the claims and believes the risk of loss remote.

From time to time, the Company may be involved in certain legal matters which arise in the normal course of operations. Management believes that the resolution of such matters will not have a material adverse effect on the financial position or results of operations of the Company.